@Article{Strojek2023,
journal="Lekarz POZ",
issn="2450-3517",
volume="9",
number="4",
year="2023",
title="Gliclazide MR – the place in modern treatment of type 2 diabetes",
abstract="In recent years, the introduction of new antihyperglicaemic drugs resulted in significant changes in pharmacotherapy regimens. Current guidelines focus on individualization of the treatment, multifactorial and behavioral management, including weight reduction. Sulfonylurea derivatives, including the gliclazide MR presented in the following study, remain an important element of therapeutic strategies. Gliclazide MR is the best-studied representative of this group. It is characterized by high safety and effectiveness, which have been confirmed in numerous clinical trials. This drug lowers glycaemia more effectively than many other antidiabetic drugs, with a much lower risk of hypoglycemia and weight gain. This study aims to indicate the place of gliclazide MR in the modern treatment of type 2 diabetes, based on the latest therapeutic recommendations and available medical data on its safety, efficacy and its impact on cardiovascular and renal vascular risk.",
author="Strojek, Krzysztof
and Zozulińska-Ziółkiewicz, Dorota Anna
and Czupryniak, Leszek
and Małecki, Maciej Tadeusz
and Kokoszka-Paszkot, Janina
and Prejbisz, Aleksander
and Dobrowolski, Piotr
and Kasprzak, Jarosław Damian
and Tomaszuk-Kazberuk, Anna",
pages="199--209",
url="https://www.termedia.pl/Gliclazide-MR-the-place-in-modern-treatment-of-type-2-diabetes,98,51543,1,1.html"
}